ISG15 and colorectal carcinoma: As previous studies have demonstrated the difference in response to immunotherapy between subcutaneous and orthotopic tumors [25,26], we aimed to evaluate whether the anti-CRC effects of Lm-LLO-ISG15 in subcutaneous tumors can also be translated to orthotopic tumors.